

Claims

1. Use of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of nonconstipated female IBS.
- 5 2. Use according to claim 1 wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative.
3. Use according to claim 2 wherein alosetron is in the form of its hydrochloride.
- 10 4. Use according to claim 1 wherein the 5-HT₃ receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron or dolasetron.
5. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof.
- 15 6. A method of treatment according to claim 5 wherein the 5-HT₃ receptor antagonist is alosetron or a pharmaceutically acceptable derivative.
7. A method of treatment according to claim 6 wherein alosetron is in the form of its hydrochloride.
- 20 8. A method of treatment according to claim 5 wherein the 5-HT₃ receptor antagonist is selected from granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron or dolasetron.
9. A 5-HT₃ receptor antagonist or a pharmaceutically acceptable derivative thereof for use in the treatment of nonconstipated female IBS.
- 25 10. A 5-HT₃ receptor antagonist according to claim 9 which is alosetron, or alosetron in the form of its hydrochloride.

Add A2
Add B3